$1.04
-0.01 (-0.95%)
Open$1.05
Previous Close$1.05
Day High$1.09
Day Low$1.04
52W High$1.80
52W Low$0.75
Volume—
Avg Volume617.0K
Market Cap16.07M
P/E Ratio—
EPS$-0.80
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+3,165.4% upside
Current
$1.04
$1.04
Target
$33.96
$33.96
$19.62
$33.96 avg
$35.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 227.0K | 590.4K | 1.55M |
| Net Income | -31,155,262 | -72,925,190 | 361.3K |
| Profit Margin | -13,700.0% | -13,015.0% | 23.4% |
| EBITDA | -30,891,690 | -76,325,371 | 534.5K |
| Free Cash Flow | — | — | 193.8K |
| Rev Growth | -61.6% | -61.6% | +15.5% |
| Debt/Equity | — | — | 1.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |